EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study



Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study



Dementia and Geriatric Cognitive Disorders 36(3-4): 229-241



To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB). This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for 2 weeks, followed by 5 mg daily for the remaining 50 weeks. Cognitive function, behavioral and psychiatric symptoms, cognitive fluctuations, and caregiver burden were assessed using the Mini-Mental State Examination, Neuropsychiatric Inventory, Cognitive Fluctuation Inventory, and the Zarit Caregiver Burden Interview, respectively. Safety parameters were monitored throughout. In total, 108 patients were enrolled in the study. Cognitive function and dementia-related behavioral symptoms, including cognitive fluctuations, were improved after the start of donepezil treatment, and improvement was maintained for 52 weeks. Reduction in caregiver burden observed in the preceding RCT returned to the baseline level at 52 weeks. There was no significant imbalance in the incidence of adverse events (AEs) by onset time, and delayed AE onset induced by the long-term administration of donepezil was unlikely to appear. The long-term administration of donepezil at 5 mg/day was well tolerated in patients with DLB and is expected to exhibit lasting effects, improving impaired cognitive function and psychiatric symptoms up to 52 weeks.

(PDF emailed within 0-6 h: $19.90)

Accession: 054171716

Download citation: RISBibTeXText

PMID: 23949147

DOI: 10.1159/000351672



Related references

Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dementia and Geriatric Cognitive Disorders 27(3): 232-239, 2009

Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimer's Research & Therapy 7(1): 5-5, 2015

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry and Clinical Neurosciences 60(2): 190-195, 2006

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dementia and Geriatric Cognitive Disorders 23(6): 401-405, 2007

Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies. Dementia and Geriatric Cognitive Disorders 40(3-4): 186-198, 2016

Results of a 24-week, open-label, flexible-dose trial to assess the safety and efficacy of galantamine in patients with dementia with Lewy bodies. Neurology 60(5 Supplement 1): A193-A194, March 11, 2003

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. European Neuropsychopharmacology 8(1): 67-75, 1998

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology 24(5): 725-733, 2015

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Modern Rheumatology 24(5): 734-743, 2015

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology 58(3): 427-433, 2001

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes, Obesity & Metabolism 20(5): 1176-1185, 2018

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clinical Therapeutics 34(10): 2091-2103, 2013

Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. International Journal of Geriatric Psychiatry 18(6): 549-551, 2003

Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies: An open-label study with actigraphy. Psychiatry Research 251: 312-318, 2017

Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine Results of a 24-week, open-label extension study in moderate to severe Alzheimers disease. European Journal of Neurology 10(Supplement 1): 160, September, 2003